• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

UPDATE - Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies.

作者信息

Kokorovic Andrea, So Alan I, Serag Hosam, French Christopher, Hamilton Robert J, Izard Jason P, Nayak Jasmir G, Pouliot Frédéric, Saad Fred, Shayegan Bobby, Aprikian Armen, Rendon Ricardo A

机构信息

Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.

Department of Urological Sciences, University of British Columbia, Vancouver, BC, Canada.

出版信息

Can Urol Assoc J. 2022 Aug;16(8):E416-E431. doi: 10.5489/cuaj.8054.

DOI:10.5489/cuaj.8054
PMID:35905482
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9343157/
Abstract
摘要

相似文献

1
UPDATE - Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies.更新——加拿大泌尿外科协会雄激素剥夺治疗指南：不良事件与管理策略
Can Urol Assoc J. 2022 Aug;16(8):E416-E431. doi: 10.5489/cuaj.8054.
2
UPDATE - Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies Summary of changes.更新 - 加拿大泌尿外科协会雄激素剥夺治疗指南：不良事件及管理策略 更改摘要
Can Urol Assoc J. 2022 Aug;16(8):243-244. doi: 10.5489/cuaj.8007.
3
Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies.加拿大泌尿外科协会雄激素剥夺治疗指南：不良事件及管理策略
Can Urol Assoc J. 2021 Jun;15(6):E307-E322. doi: 10.5489/cuaj.7355.
4
Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies - Executive summary.加拿大泌尿外科协会雄激素剥夺治疗指南：不良事件与管理策略——执行摘要
Can Urol Assoc J. 2021 Jun;15(6):159-161. doi: 10.5489/cuaj.7357.
5
Qualitative Review of Clinical Guidelines for Medical and Surgical Management of Urolithiasis: Consensus and Controversy 2020.2020 年尿石症医学和外科治疗临床指南的定性评价：共识与争议
J Urol. 2021 Apr;205(4):999-1008. doi: 10.1097/JU.0000000000001478. Epub 2020 Dec 7.
6
The American Urological Association 2003 guideline on management of benign prostatic hyperplasia: a Canadian opinion.美国泌尿外科学会2003年良性前列腺增生管理指南：加拿大的观点。
Can J Urol. 2004 Apr;11(2):2186-93.
7
UPDATE - Canadian Urological Association guideline: Evaluation and medical management of kidney stones.更新 - 加拿大泌尿外科学会指南：肾结石的评估与药物治疗
Can Urol Assoc J. 2022 Jun;16(6):175-188. doi: 10.5489/cuaj.7872.
8
UPDATE - 2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) castration-resistant prostate cancer (CRPC) guideline: What has changed since 2019?更新 - 2021年加拿大泌尿外科协会（CUA）-加拿大泌尿肿瘤学组（CUOG）去势抵抗性前列腺癌（CRPC）指南：自2019年以来有哪些变化？
Can Urol Assoc J. 2021 Feb;15(2):11-12. doi: 10.5489/cuaj.7160.
9
Management of the side effects of androgen deprivation therapy in men with prostate cancer.前列腺癌男性患者雄激素剥夺治疗副作用的管理
Expert Opin Pharmacother. 2008 Nov;9(16):2829-41. doi: 10.1517/14656566.9.16.2829.
10
UPDATE - Canadian Urological Association guideline: Male lower urinary tract symptoms/benign prostatic hyperplasia.更新 - 加拿大泌尿外科协会指南：男性下尿路症状/良性前列腺增生
Can Urol Assoc J. 2022 Aug;16(8):245-256. doi: 10.5489/cuaj.7906.

引用本文的文献

1
Taiwan Consensus for the Management of Cardiovascular Risks and Complications in Patients with Prostate Cancer.《前列腺癌患者心血管风险与并发症管理台湾共识》
Acta Cardiol Sin. 2025 May;41(3):288-310. doi: 10.6515/ACS.202505_41(3).20250224A.
2
Management of vasomotor symptoms in cancer patients.癌症患者血管舒缩症状的管理
Oncologist. 2025 Feb 6;30(2). doi: 10.1093/oncolo/oyaf002.
3
Screening and management of metabolic, cardiac, and bone health in prostate cancer patients on androgen deprivation therapy A survey of specialized physicians.接受雄激素剥夺治疗的前列腺癌患者代谢、心脏及骨骼健康的筛查与管理：专科医生调查
Can Urol Assoc J. 2024 Jun;18(6):212-215. doi: 10.5489/cuaj.8687.
4
Cardiologist-Performed Baseline Evaluation with an Assessment of Coronary Status for Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: Impact on Newly Diagnosed Coronary Artery Disease.心脏病专家对接受雄激素剥夺治疗的前列腺癌患者进行冠状动脉状况评估的基线评估：对新诊断冠状动脉疾病的影响。
Cancers (Basel). 2023 Aug 17;15(16):4157. doi: 10.3390/cancers15164157.
5
Insights Into the Cardiomodulatory Effects of Sex Hormones: Implications in Transgender Care.深入了解性激素的心脏调节作用：对跨性别护理的影响。
Hypertension. 2023 Sep;80(9):1810-1820. doi: 10.1161/HYPERTENSIONAHA.123.19501. Epub 2023 Jul 18.

本文引用的文献

1
Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial.前列腺癌患者中地加瑞克与亮丙瑞林的心血管安全性：PRONOUNCE 随机试验的主要结果。
Circulation. 2021 Oct 19;144(16):1295-1307. doi: 10.1161/CIRCULATIONAHA.121.056810. Epub 2021 Aug 30.
2
2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults.2021 加拿大心血管学会成人血脂异常管理指南：预防心血管疾病
Can J Cardiol. 2021 Aug;37(8):1129-1150. doi: 10.1016/j.cjca.2021.03.016. Epub 2021 Mar 26.
3
2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC).2021年加拿大泌尿外科学会（CUA）-加拿大泌尿肿瘤学组（CUOG）指南：去势抵抗性前列腺癌（CRPC）的管理
Can Urol Assoc J. 2021 Feb;15(2):E81-E90. doi: 10.5489/cuaj.7074.
4
The Risk of New Onset Dementia and/or Alzheimer Disease among Patients with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis.雄激素剥夺治疗的前列腺癌患者新发痴呆症和/或阿尔茨海默病风险：系统评价和荟萃分析。
J Urol. 2021 Jan;205(1):60-67. doi: 10.1097/JU.0000000000001341. Epub 2020 Aug 28.
5
Neuropsychiatric Impact of Androgen Deprivation Therapy in Patients with Prostate Cancer: Current Evidence and Recommendations for the Clinician.雄激素剥夺疗法对前列腺癌患者的神经精神影响：当前证据和临床建议。
Eur Urol Focus. 2020 Nov 15;6(6):1170-1179. doi: 10.1016/j.euf.2020.05.014. Epub 2020 Jul 18.
6
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.口服瑞戈非尼在晚期前列腺癌中的雄激素剥夺治疗。
N Engl J Med. 2020 Jun 4;382(23):2187-2196. doi: 10.1056/NEJMoa2004325. Epub 2020 May 29.
7
Neoadjuvant Leuprolide Therapy with Radical Prostatectomy: Long-term Effects on Health-related Quality of Life.新辅助性亮丙瑞林治疗联合根治性前列腺切除术：对健康相关生活质量的长期影响。
Eur Urol Focus. 2021 Jul;7(4):779-787. doi: 10.1016/j.euf.2020.03.001. Epub 2020 Mar 9.
8
Bone Health and Bone-Targeted Therapies for Prostate Cancer: American Society of Clinical Oncology Endorsement Summary of a Cancer Care Ontario Guideline.前列腺癌的骨骼健康与骨靶向治疗：美国临床肿瘤学会对安大略癌症护理指南的认可总结
JCO Oncol Pract. 2020 Jul;16(7):389-393. doi: 10.1200/JOP.19.00778. Epub 2020 Feb 19.
9
Exercise Guidelines for Cancer Survivors: Consensus Statement from International Multidisciplinary Roundtable.癌症康复者运动指南：国际多学科圆桌会议的共识声明。
Med Sci Sports Exerc. 2019 Nov;51(11):2375-2390. doi: 10.1249/MSS.0000000000002116.
10
Responsiveness to Resistance-Based Multimodal Exercise Among Men With Prostate Cancer Receiving Androgen Deprivation Therapy.雄激素剥夺治疗的前列腺癌男性患者对基于抵抗的多模式运动的反应。
J Natl Compr Canc Netw. 2019 Oct 1;17(10):1211-1220. doi: 10.6004/jnccn.2019.7311.